Clinical markers and outcomes of neonates with herpes simplex virus deoxyribonucleic acid persistence in cerebrospinal fluid in disseminated and central nervous system infection

Creator(s)

William R. Otto, Children's Mercy Hospitals and Clinics
Angela L. Myers, Children's Mercy Hospitals and Clinics
Barrett LaRussa, The University of Alabama at Birmingham
David W. Kimberlin, The University of Alabama at Birmingham
Mary Anne Jackson, Children's Mercy Hospitals and Clinics

Document Type

Article

Publication Date

5-15-2018

Identifier

DOI: 10.1093/jpids/pix033

Abstract

© The Author(s) 2017. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved.

We compared the clinical course of neonates with persistence of herpes simplex virus (HSV) deoxyribonucleic acid (DNA) in the cerebrospinal fluid (CSF) after 21 days of treatment with high-dose acyclovir to that of neonates with clearance of the CSF after 21 days of therapy. Neonates with persistence of HSV DNA had a more severe clinical course with worse neurodevelopmental outcomes.

Journal Title

Journal of the Pediatric Infectious Diseases Society

Volume

7

Issue

2

First Page

E30

Last Page

E33

Keywords

Acyclovir; Central nervous system; Herpes simplex virus; HSV; Neonate

Recommended Citation

Otto WR, Myers AL, LaRussa B, Kimberlin DW, Jackson MA. Clinical Markers and Outcomes of Neonates With Herpes Simplex Virus Deoxyribonucleic Acid Persistence in Cerebrospinal Fluid in Disseminated and Central Nervous System Infection. J Pediatric Infect Dis Soc. 2018;7(2):e30-e33. doi:10.1093/jpids/pix033